Aduro Biotech Культура компании

Mr. Stephen T. Isaacs, also known as Steve, has been the Chairman, Chief Executive Officer and President of Aduro BioTech, Inc. since 2008. Mr. Isaacs was the founder of Cerus Corporation and served as its President and Chief Executive Officer from September 1991 to May 10, 2004. While at Cerus, he led financings and partnerships providing over $250 million and negotiated major contracts with Baxter Healthcare Inc., the Consortium for Plasma Science, Kirin Pharmaceuticals and the Medimmune Corporation. Mr. Isaacs also led the Cerus initial public offering in 1997. Prior to Cerus, Mr. Isaacs served as the President and Chief Executive Officer of HRI Research from 1983 to 1991 and HRI Associates from 1979 to 1983.He has been a Director of Aduro BioTech, Inc. since 2008. He served as Director of Cerus Corporation from September 1991 to May 10, 2004. He held a research position in the Department of Chemistry at the University of California at Berkeley from 1975 to 1986. He has authored 20 scientific publications and holds 42 patents. Mr. Isaacs received his undergraduate degree in Biochemistry from University of California at Berkeley in 1973.

Mr. Blaine E. Templeman has been an Executive Vice President, General Counsel and Secretary of Aduro BioTech, Inc. since September 21, 2015. Mr. Templeman served as Managing Partner of New York Office at Sheppard, Mullin, Richter & Hampton LLP. Mr. Templeman served as a Partner of the Intellectual Property Practice Group in the New York office at Sheppard, Mullin, Richter & Hampton LLP. Mr. Templeman has over 20 years of experience counseling biotechnology companies in the development and commercialization of their products and the protection of their intellectual property portfolios. Mr. Templeman was a Shareholder at Heller Ehrman LLP since May 2006 and was a Member of the Intellectual Property Transactions, Life Sciences and Corporate/VLG Practice Groups. Prior to joining Aduro, Mr. Templeman was a Corporate and Intellectual Property Partner at Arnold & Porter LLP, where he counseled U.S. and international clients on the protection, development and commercialization of their products, intellectual property portfolios, contract manufacturing, clinical trials, research and outsourcing. His transactional experience includes a variety of collaborations, licensing transactions, mergers and acquisitions, asset sales, manufacturing and distribution arrangements and co-promotion transactions. Before Arnold & Porter LLP, he was a partner at Heller Ehrman. Mr. Templeman's practice focuses on strategic intellectual property transactions and drug and device discovery and development, including licensing, collaborations, copromotions, joint venture clinical trials, manufacturing and CRO and other service provider arrangements. In the past 12 months, Mr. Templeman has managed transactions valued at more than $1.5 billion, including mergers and acquisitions, collaborations, licensing deals and clinical trials. Mr. Templeman has also counseled media clients in transactions with service providers and potential partners and in connection with technology licenses. Mr. Templeman regularly provides counsel to a variety of drug and device discovery and development companies and pharmaceutical companies in connection with clinical study protocols, clinical trial agreements, patient informed consents, materials transfer agreements, sponsored research agreements, license agreements, collaboration agreements, development agreements and manufacturing and supply agreements. He has worked closely with several of his clients to complete technology licensing, collaboration and distribution deals in Australia, Japan, the EU and the US. He has also partnered with his clients to initiate and conduct clinical trials at more than 300 sites around the world, as well as contracted with a multiplicity of contract manufacturers, CROs, laboratories and consultants. He was a Member of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Mr. Templeman holds J.D. from New York University School of Law in 1994 and B.A. from Oral Roberts University in 1988.

Mr. Gregory W. Schafer, also known as Greg, MBA, has been the Chief Operating Officer of Aduro BioTech, Inc. since July 23, 2013. Mr. Schafer has more than 23 years of broad operational, financial and strategic leadership expertise. He served as the Chief Financial Officer and Senior Vice President at Jennerex Biotherapeutics, Inc. (Alternate Name, Jennerex, Inc) since June 22, 2010. From April 2009 to June 2010, Mr. Schafer served as an independent consultant to private and public biotechnology companies. He served as Chief Financial Officer, Principal Accounting Officer and Vice President of Onyx Pharmaceuticals Inc. until January 5, 2009 and served as its Acting Chief Financial Officer since April 12, 2006. From September 2004 to 2006, Mr. Schafer served as a Financial Consultant to various companies in the biotechnology industry. He served as Chief Financial Officer of Intrabiotics Pharmaceuticals Inc. from March 10, 2005 to August 19, 2005. He served as Financial Consultant of Intrabiotics Pharmaceuticals Inc. since January 2004. He served as Acting Chief Financial Officer of NeoRx Corporation from September 2004 to November 2004. Mr. Schafer served as Chief Financial Officer and Vice President of Finance at Cerus Corporation from May 1999 to August 2004, Director of Finance from May 1997 to May 1999 and also served as its Principal Accounting Officer. Prior to joining Cerus, Mr. Schafer served as a Management Consultant for Deloitte & Touche LLP from August 1992 to September 1995. He was an Engineer specializing in biologics manufacturing. He served as an Independent Management Consultant from September 1995 to April 1997. He served as a Director of Capricor Therapeutics, Inc. from January 2008 to June 02, 2016. He served as Director of Nile Therapeutics, Inc since January 2008. Mr. Schafer holds an MBA from the Anderson Graduate School of Management at UCLA and BSE in Mechanical Engineering from the University of Pennsylvania.

Dr. Natalie R. Sacks, M.D., has been Chief Medical Officer of Aduro BioTech, Inc. since September 2016. Dr. Sacks has clinical background as well as her broad experience in all aspects of product development is from global clinical and regulatory strategy through reimbursement and expansion indications is instrumental in guiding internal and partnered programs. Prior to joining Aduro, Dr. Sacks served as an Advisor on development strategy for multiple firms. She served as Vice President of Clinical Development at Onyx Pharmaceuticals where she served a key role in the development and approval of Kyprolis?? and in business development strategy. She served as Vice President of Clinical Research for Exelixis where she directed the development of a portfolio of small molecules, ranging from IND filing to late-stage development, including Cometriqa. She served positions of increasing responsibility at Cell Genesys, culminating as Vice President of Clinical Development. She served in a variety of research and analytical roles at academic institutions and companies including Massachusetts General Hospital, Medical College of Pennsylvania and ICI-Stuart Pharmaceuticals. She has been a Director of Zymeworks Inc. since August 03, 2017. Dr. Sacks holds an active faculty appointment at the University of California, San Francisco (UCSF) where she is an assistant clinical professor of medicine in the Division of Hematology/Oncology. She received her M.D. from the University of Pennsylvania School of Medicine, her M.S. in Biostatistics from Harvard University School of Public Health and her B.A. in Mathematics from Bryn Mawr College.

Dr. Hans van Eenennaam, Ph.D. has been Chief Operating Officer of Europe at Aduro BioTech, Inc., since November 2015. Dr. van Eenennaam serves as Chief Operational Officer of BioNovion B.V. He joined Organon in 2002 in Oss and is responsible for Organon's proprietary monoclonal antibody platform. In 2005, he joined the Organon Research Center in Cambridge, MA, where he supervised antibody discovery programs and ran the Center's daily operations. After joining Schering-Plough in 2007, he became Section Head Inflammation and Lead Finding Team leader Immunology. He delivered the supporting biology data for three Lead Optimization programs and two Pre-Clinical Candidates. Dr. van Eenennaam has optimized the antibody platform technology and discovered several antibody leads for Organon and Schering-Plough that reached preclinical and clinical stages. Collaborating with his academic partners in the Top Institute Pharma program TNF ligands in Cancer' he discovered the antibody leads that BioNovion acquired. He is a co-founder of BioNovion. Dr. van Eenennaam is a chemist by training and received his Ph.D. in the field of Autoimmune Biochemistry at the Radboud University Nijmegen (cum laude).

Mr. Peter M. Lauer, Ph.D. serves as Head of Molecular Biology at Aduro BioTech, Inc. Mr. Lauer has over 10 years of experience in research and microbial vaccine development. He is an inventor on US patents and patent applications for the discovery of novel molecular tools for Listeria vaccine strain development. Mr. Lauer received his Ph.D. in Molecular and Cell Biology at University of California, Berkeley studying the genetics of intracellular L. monocytogenes motility. Mr. Lauer did his post-doctoral research on bacterial vaccines development in Siena, Italy at Chiron Vaccines.

Greg Schafer serves as the COO of Aduro Biotech, Inc.. Greg started at Aduro Biotech, Inc. in July of 2013. Greg currently resides in San Francisco Bay Area.

Jennifer Lew serves as the Senior Vice President, Finance of Aduro Biotech, Inc.. Jennifer started at Aduro Biotech, Inc. in October of 2013. Jennifer currently resides in San Francisco Bay Area.

Noopur Liffick serves as the Executive Director, Investor Relations / Corporate Affairs of Aduro Biotech, Inc.. Noopur started at Aduro Biotech, Inc. in October of 2018. Noopur currently resides in San Francisco Bay Area.